Drug Approval | June 27, 2024
Shilpa Medicare Bio Analytical unit gets "No Action Indicated" classification from USFDA
This Unit of Shilpa Medicare is engaged in testing biological samples of clinical studies
This Unit of Shilpa Medicare is engaged in testing biological samples of clinical studies
Company's Unit - IX, an API intermediate facility situated at Sangareddy District, Telangana, has now been classified as Voluntary Action Indicated
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
The IDCF programme is being implemented from 13th June to 27th June, 2022 in the states/UTs and the goal is to attain zero child deaths due to childhood diarrhoea
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
Achieving ML 4 brings Singapore closer to becoming a WHO listed authority, a new scheme that will be operational later this year and will list the world’s regulators of reference
The newly classified assays join Roche’s Ionify 25-Hydroxy Vitamin D total assay in a growing U.S. portfolio
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
One task, one interaction, one pair, experts advocate
Subscribe To Our Newsletter & Stay Updated
